In reaction to strong earnings/guidance:
- PII +10%, LOGI +6.2%, GPK +5.4%, AUDC +5.2%, FBP +4.9%, CETV +4%, DGX +4%, PNR +3.7%, SAN +3.6%, IRDM +3.5%, ATI +3.1%, EDU +3%, HAS +2.9%, FBC +2.5%, KO +2.5%, SHW +2.5%, LMT +2.5%, SWK +2.4%, PHM +2.4%, UTX +2.3%, JBLU +2.3%, UBS +2.1%, HXL +2%, KMB +2%, CR +1.3%, ASR +1.2%, ACC +1%, BRO +1%, MTG +0.8%, LPL +0.7%, BIIB +0.5%
M&A news:
- INTC +1.2% (WSJ reporting that Apple (AAPL) may buy Intel's smartphone-modem chip unit)
Other news:
- RLGY +39% (Realogy & Amazon (AMZN) partner to launch TurnKey)
- CHMA +28.1% (announced 'positive' top-line data from its Phase 3 CHIASMA OPTIMAL clinical trial evaluating Mycapssa for the maintenance treatment of adults with acromegaly)
- MYOV +26.9% (to host call at 8:30 a.m. ET tomorrow to discuss results from second Phase 3 study evaluating once-daily relugolix combination therapy in women with uterine fibroids and from bioequivalence study)
- AVCO +10.2% (established strategic partnership with GE Healthcare)
- MRNS +4.8% (reports data from Magnolia and Amaryllis Phase 2 studies in women with postpartum depression)
- MAXR +2.3% (chosen by NASA to integrate pollution monitoring payload on an upcoming commercial satellite)
Analyst comments:
- INFN +6.5% (upgraded to Buy at B. Riley FBR)
- KPTI +6.2% (upgraded to Overweight from Neutral at JP Morgan)
- SNAP +3.2% (upgraded to Buy from Hold at Stifel; initiated with Buy at Rosenblatt)
- VFF +3% (initiated with Buy at Craig Hallum)
- COLM +2% (upgraded to Buy from Neutral at BofA/Merrill)
- MUR +1.4% (upgraded to Buy from Neutral at Goldman)